Literature DB >> 17077342

Glucocorticoids produce whole body insulin resistance with changes in cardiac metabolism.

Dake Qi1, Brian Rodrigues.   

Abstract

Insulin resistance is viewed as an insufficiency in insulin action, with glucocorticoids being recognized to play a key role in its pathogenesis. With insulin resistance, metabolism in multiple organ systems such as skeletal muscle, liver, and adipose tissue is altered. These metabolic alterations are widely believed to be important factors in the morbidity and mortality of cardiovascular disease. More importantly, clinical and experimental studies have established that metabolic abnormalities in the heart per se also play a crucial role in the development of heart failure. Following glucocorticoids, glucose utilization is compromised in the heart. This attenuated glucose metabolism is associated with altered fatty acid supply, composition, and utilization. In the heart, elevated fatty acid use has been implicated in a number of metabolic, morphological, and mechanical changes and, more recently, in "lipotoxicity". In the present article, we review the action of glucocorticoids, their role in insulin resistance, and their influence in modulating peripheral and cardiac metabolism and heart disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17077342     DOI: 10.1152/ajpendo.00453.2006

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  57 in total

Review 1.  Role of dual specificity phosphatases in biological responses to glucocorticoids.

Authors:  Andrew R Clark; Joana R S Martins; Carmen R Tchen
Journal:  J Biol Chem       Date:  2008-06-09       Impact factor: 5.157

2.  Dose Dependent Hepatic and Endothelial Changes in Rats Treated with Dexamethasone.

Authors:  V Hemanth Kumar; Nagendra Nayak Im; Shobha V Huilgol; Saeed M Yendigeri; Narendar K; Rajasekhar Ch
Journal:  J Clin Diagn Res       Date:  2015-05-01

3.  Echocardiographic alterations in patients with non-functioning adrenal incidentaloma.

Authors:  F Ermetici; C Dall'Asta; A E Malavazos; C Coman; L Morricone; V Montericcio; B Ambrosi
Journal:  J Endocrinol Invest       Date:  2008-06       Impact factor: 4.256

4.  Tissue-specific difference in the molecular mechanisms for the development of acute insulin resistance after injury.

Authors:  Li Li; LaWanda H Thompson; Ling Zhao; Joseph L Messina
Journal:  Endocrinology       Date:  2008-09-18       Impact factor: 4.736

Review 5.  Role of addiction and stress neurobiology on food intake and obesity.

Authors:  Rajita Sinha
Journal:  Biol Psychol       Date:  2017-05-04       Impact factor: 3.251

6.  Use of continuous glucose monitoring to estimate insulin requirements in patients with type 1 diabetes mellitus during a short course of prednisone.

Authors:  Wendy C Bevier; Howard C Zisser; Lois Jovanovic; Daniel A Finan; Cesar C Palerm; Dale E Seborg; Francis J Doyle
Journal:  J Diabetes Sci Technol       Date:  2008-07

7.  Model-based insulin sensitivity as a sepsis diagnostic in critical care.

Authors:  Amy Blakemore; Sheng-Hui Wang; Aaron Le Compte; Geoffrey M Shaw; Xing-Wei Wong; Jessica Lin; Thomas Lotz; Christopher E Hann; J Geoffrey Chase
Journal:  J Diabetes Sci Technol       Date:  2008-05

8.  Effects of excess corticosterone on LKB1 and AMPK signaling in rat skeletal muscle.

Authors:  G Nathan Nakken; Daniel L Jacobs; David M Thomson; Natasha Fillmore; William W Winder
Journal:  J Appl Physiol (1985)       Date:  2009-12-03

9.  Pharmacogenetic interaction between dexamethasone and Cd36-deficient segment of spontaneously hypertensive rat chromosome 4 affects triacylglycerol and cholesterol distribution into lipoprotein fractions.

Authors:  Michaela Krupková; Lucie Sedová; Frantisek Liska; Drahomíra Krenová; Vladimír Kren; Ondrej Seda
Journal:  Lipids Health Dis       Date:  2010-04-16       Impact factor: 3.876

Review 10.  Why pleiotropic interventions are needed for Alzheimer's disease.

Authors:  Sally A Frautschy; Greg M Cole
Journal:  Mol Neurobiol       Date:  2010-05-02       Impact factor: 5.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.